Markets:

Overview

News

Currencies

International

Treasuries

Tenax Therapeutics, Inc. - Common Stock (NQ:TENX)

12.85 -0.42 (-3.17%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Tenax Therapeutics, Inc. - Common Stock

Tenax Therapeutics Inc. (NASDAQ: TENX) Near the Top of Equities by Percentage Gain on 2/6

February 06, 2024

Via Investor Brand Network

InvestorNewsBreaks – Tenax Therapeutics Inc. (NASDAQ: TENX) Announces $15.6M Public Offering

February 10, 2023

Via Investor Brand Network

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 02, 2023

Tenax Therapeutics, Inc. (NASDAQ: TENX) is engaged as a specialty pharmaceutical company, which is focused on the research, development and

Via Spotlight Growth

Topics Intellectual Property

Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)

May 25, 2022

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

May 23, 2022

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

May 18, 2022

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

March 31, 2022

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

March 30, 2022

From Tenax Therapeutics, Inc.

Via Business Wire

NASDAQ:TENX Shareholder Alert: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc. ↗

February 17, 2022

San Diego, CA -- (SBWIRE) -- 02/17/2022 -- Certain directors of Tenax Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties .

Via SBWire

Investigation for Investors in Tenax Therapeutics, Inc. (NASDAQ:TENX) Shares Announced ↗

December 13, 2021

San Diego, CA -- (SBWIRE) -- 12/13/2021 -- An investigation was announced for investors of Tenax Therapeutics, Inc. (NASDAQ:TENX) shares over potential securities laws violations by Tenax Therapeutics,...

Via SBWire

NASDAQ:TENX Investor Notice: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc. ↗

December 01, 2021

San Diego, CA -- (SBWIRE) -- 12/01/2021 -- Certain directors of Tenax Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Via SBWire

Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

November 16, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

NASDAQ:TENX Investor Notice: Investigation over Possible Securities Laws Violations by Tenax Therapeutics, Inc. ↗

November 09, 2021

San Diego, CA -- (SBWIRE) -- 11/09/2021 -- Tenax Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

October 06, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference

September 28, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 09, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

August 17, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

August 12, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

August 05, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

July 07, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Set to Join Russell Microcap® Index

June 10, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

May 17, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”

April 09, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders

April 07, 2021

From Tenax Therapeutics, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.